☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
advanced renal cell carcinoma
Merck's Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive the US FDA's Approval as 1L Treatment of Advanced Renal Cell Carci...
August 12, 2021
PharmaShots Interview: Ipsen's Dr. Med. Steven Hildemann Shares Insight on the EC's Approval of Cabometyx + Nivolumab for Advanced...
May 11, 2021
Merck and Eisai Receive the US FDA‘s Priority Review for Keytruda (pembrolizumab) + Lenvima (lenvatinib) to Treat Advanced Renal C...
May 7, 2021
AVEO Oncology's Fotivda (tivozanib) Receives the US FDA's Approval for the Treatment of R/R Advanced Renal Cell Carcinoma
March 10, 2021
Exelixis Cabometyx (cabozantinib) + Opdivo (nivolumab) Receives US FDA's Approval as a 1L Treatment for Patients with Advanced Ren...
January 25, 2021
Pfizer's Bavencio (avelumab) + Axitinib Dual Regimen Receive EC's Approval as 1L Treatment for Advanced Renal Cell Carcinoma
October 29, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.